Tumors have learned to hide from the immune system. This work teaches the body to see them again.
Each year, liver cancer quietly claims tens of thousands of American lives, yet its survival rates have remained among the lowest of any malignancy for decades. In response, the National Institutes of Health has invested $3.9 million in a collaboration between the Terasaki Institute and Mayo Clinic — an effort to move beyond the blunt instrument of systemic chemotherapy and toward a more precise, dual-front assault on tumors. The researchers seek to refine an existing technique that delivers drugs directly into tumors while adding immunotherapy to reawaken the body's own defenses, recognizing that neither approach alone has been enough. It is, at its heart, a wager that precision and partnership — between science and the immune system — can finally move numbers that suffering has long held still.
- Liver cancer kills roughly fifty thousand Americans annually, yet five-year survival rates remain in the single digits — a crisis that decades of research have barely dented.
- Conventional chemotherapy floods the entire body with toxins, ravaging healthy tissue while often failing to eliminate the tumor it was meant to destroy.
- A $3.9 million NIH grant is now funding a smarter approach: engineering slow-release particles that concentrate chemotherapy directly at the tumor site through a catheter-guided technique called TACE.
- Alongside the refined drug delivery, researchers will deploy immunotherapy agents designed to strip tumors of their ability to hide from the immune system, turning the patient's own white blood cells into a second line of attack.
- The combined strategy is still years from clinical application, but for patients with few options and almost no curative alternatives, it represents one of the most promising openings in liver cancer research in recent memory.
Liver cancer remains one of the most lethal and least treatable malignancies in the United States. With a five-year survival rate of just three percent for metastatic cases and nine percent when the disease is confined to the organ, the numbers have barely moved despite decades of effort — even as diagnoses have risen four percent over the last ten years.
The National Institutes of Health has now committed $3.9 million to researchers Ali Khademhosseini of the Terasaki Institute for Biomedical Innovation and Rami Oklu of the Mayo Clinic, charging them with engineering a more intelligent way to fight the disease. Their target is a technique already in use called trans-arterial chemoembolization, or TACE, in which a catheter delivers chemotherapy directly into the artery feeding a tumor while simultaneously blocking its blood supply. It outperforms systemic chemotherapy, but its effects are temporary — drugs disperse, tumors adapt, patients relapse.
Khademhosseini's team will redesign the particles used in TACE to release drugs more slowly and precisely, sustaining therapeutic concentrations at the tumor site for longer. Crucially, they will pair this with immunotherapy agents that dismantle the tumor's ability to evade the immune system — restoring the body's own capacity to recognize and destroy what remains after chemotherapy has done its work.
Liver transplantation is the only known cure for advanced disease, but donor scarcity places it out of reach for most patients. Surgery is viable only in a minority of early-stage cases. For the tens of thousands of Americans who fall outside those narrow windows each year, this research offers something rare: a genuinely new direction, built on the belief that precision delivery and a reawakened immune response, working together, might finally change what survival looks like.
Liver cancer kills roughly one in every twelve Americans who die of cancer each year—about fifty thousand people annually—yet it remains one of the hardest malignancies to treat. The five-year survival rate for patients whose disease has spread beyond the liver sits at just three percent. For those whose cancer is still contained to the organ, it's nine percent. These numbers have barely budged despite decades of research, and the disease itself is becoming more common, with cases rising four percent over the last decade.
Now the National Institutes of Health has committed $3.9 million to change that trajectory. The money will flow to Ali Khademhosseini, who directs the Terasaki Institute for Biomedical Innovation in Los Angeles, and Rami Oklu, an oncologist at the Mayo Clinic. Their collaboration will attempt to engineer a smarter way to deliver cancer-killing drugs directly into liver tumors while simultaneously awakening the body's own immune system to finish the job.
The problem with current treatment is blunt. Systemic chemotherapy—drugs injected into the bloodstream—floods the entire body with poison in hopes of killing cancer cells faster than it kills everything else. But liver tumors sit surrounded by healthy tissue that the drugs cannot distinguish from malignant cells. Patients endure severe side effects: nausea, organ damage, immune collapse. And the cancer often survives anyway.
There is a better existing technique called trans-arterial chemoembolization, or TACE. A radiologist threads a catheter into the artery feeding a tumor, then releases tiny particles that block blood flow while simultaneously delivering chemotherapy drugs directly to the cancer. The restricted blood supply concentrates the medication around the tumor cells while starving them of oxygen. It works better than systemic chemotherapy, but it is still imperfect. The drugs eventually wash away. The tumor adapts. Patients relapse.
Khademhosseini's team, which specializes in biomaterials and personalized medicine, will refine TACE into something more durable and precise. They will engineer particles that release drugs more slowly and controllably, keeping therapeutic concentrations at the tumor site longer. But they will also add a second weapon: immunotherapy drugs that reverse the tumor's ability to hide from the immune system. Cancer cells are masters at suppressing the body's natural defenses. Immunotherapeutic agents can restore those defenses, turning the patient's own white blood cells into assassins.
The strategy is elegant in its simplicity: use improved TACE to deliver chemotherapy that destroys tumor cells directly, while simultaneously injecting immunotherapy that tells the body to recognize and attack what remains. Neither approach alone has proven sufficient. Together, the researchers believe, they might finally shift the survival numbers in a meaningful direction.
Liver transplantation remains the only cure for advanced disease, but donor organs are scarce and most patients will never receive one. Surgery to remove tumors works only when the cancer is small and localized—a minority of cases. For everyone else, this research represents a genuine opening. The work will take years. But for fifty thousand Americans dying of liver cancer each year, the possibility that a smarter delivery system and a restored immune response might extend their lives is worth the wait.
Notable Quotes
Current systemic chemotherapy damages healthy tissue surrounding tumors and causes severe side effects, while improved TACE delivery combined with immunotherapy could target cancer more precisely— Research approach described in NIH grant
The Hearth Conversation Another angle on the story
Why does liver cancer have such dismal survival rates compared to other cancers?
It's partly biology and partly timing. Liver tumors are often caught late because the organ doesn't hurt until damage is severe. But the bigger problem is that current drugs can't reach the cancer without poisoning the patient. You're essentially trying to kill a tumor while keeping the organ it lives in alive.
So TACE is already being used. What's the innovation here?
TACE works, but it's temporary. The particles eventually dissolve, the drug washes away, and the tumor comes back. Khademhosseini's team is engineering particles that release medication slowly and steadily, keeping the poison concentrated where it needs to be for weeks instead of days.
And the immunotherapy piece—why add that?
Because tumors are clever. They've evolved to turn off the immune system's alarm bells. A cancer cell can sit next to a white blood cell and the immune cell won't recognize it as a threat. Immunotherapy drugs flip that switch back on. You're not just poisoning the tumor; you're recruiting the body's own army to finish it.
Is this combination approach being tested elsewhere?
Not in this specific form for liver cancer. That's why the NIH funded it. The idea of combining better drug delivery with immune activation is sound, but the engineering—getting both drugs to the right place at the right time—that's the hard part.
What happens if it works?
You could see survival rates move from single digits to something meaningful. Not a cure for everyone, but for some patients, years of life they wouldn't otherwise have had. That's the threshold that matters in cancer medicine.